Tricuspid regurgitation (TR) is a common manifestation of valvular heart disease (VHD) and affects 65–85% of the population. The primary cause is usually congenital, rheumatic, neoplastic, traumatic, or medically induced changes in the structure and morphology of the tricuspid valve. However, the pathogenesis and pathophysiology of TR have not yet been fully elucidated. TR is often associated with pulmonary hypertension, right heart dysfunction, and left heart valve surgery.
Current treatment for TR includes conservative and surgical management. The progression of TR under conservative treatment may lead to severe right heart insufficiency and consequent stasis of the circulation. Surgical treatment includes tricuspid valvuloplasty and tricuspid valve replacement. In most cases, TR is secondary to a left heart valve lesion and is treated concurrently with the replacement of the left heart valve. However, the progression and the intervention timing remain to be discussed. The intervention methods for TR have been developed in recent years, including transcatheter annuloplasty, leaflet edge-to-edge techniques, transcatheter prosthetic valve replacement, and percutaneous ectopic tricuspid valve placement. As the tricuspid valve is no longer the “forgotten valve”, it is important to raise awareness of the etiology, clinical presentation, diagnosis, treatment, and prognosis of TR. This research project aims to recruit studies about TR from pathophysiology to clinical management.
We welcome submissions in the subtopics, but not limited to:
1) The anatomy and physiopathology change in TR.
2) The imaging and cardiac functional evaluations (including echocardiography, CT and MRI scanning) in TR.
3) Metabolomics of TR or TR-induced heart failure.
4) The epidemiology, etiology, diagnosis, risk-stratification of TR.
5) The current pharmacological therapy and surgical treatment for TR.
6) The management and prognosis of TR in patients undergoing other cardiac surgery (e.g., CABG, other valve replacement, left ventricular assist device).
7) The new therapeutic approach in TR, especially regarding the treatment of transcatheter tricuspid valve placement or repair.
Tricuspid regurgitation (TR) is a common manifestation of valvular heart disease (VHD) and affects 65–85% of the population. The primary cause is usually congenital, rheumatic, neoplastic, traumatic, or medically induced changes in the structure and morphology of the tricuspid valve. However, the pathogenesis and pathophysiology of TR have not yet been fully elucidated. TR is often associated with pulmonary hypertension, right heart dysfunction, and left heart valve surgery.
Current treatment for TR includes conservative and surgical management. The progression of TR under conservative treatment may lead to severe right heart insufficiency and consequent stasis of the circulation. Surgical treatment includes tricuspid valvuloplasty and tricuspid valve replacement. In most cases, TR is secondary to a left heart valve lesion and is treated concurrently with the replacement of the left heart valve. However, the progression and the intervention timing remain to be discussed. The intervention methods for TR have been developed in recent years, including transcatheter annuloplasty, leaflet edge-to-edge techniques, transcatheter prosthetic valve replacement, and percutaneous ectopic tricuspid valve placement. As the tricuspid valve is no longer the “forgotten valve”, it is important to raise awareness of the etiology, clinical presentation, diagnosis, treatment, and prognosis of TR. This research project aims to recruit studies about TR from pathophysiology to clinical management.
We welcome submissions in the subtopics, but not limited to:
1) The anatomy and physiopathology change in TR.
2) The imaging and cardiac functional evaluations (including echocardiography, CT and MRI scanning) in TR.
3) Metabolomics of TR or TR-induced heart failure.
4) The epidemiology, etiology, diagnosis, risk-stratification of TR.
5) The current pharmacological therapy and surgical treatment for TR.
6) The management and prognosis of TR in patients undergoing other cardiac surgery (e.g., CABG, other valve replacement, left ventricular assist device).
7) The new therapeutic approach in TR, especially regarding the treatment of transcatheter tricuspid valve placement or repair.
